Valion Bio, Inc. (VBIO) income statement
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.50−0.04 (-7.55%)
Close on Nov 18, 2026Market cap $2.09MP/E –Yield –
Valion Bio, Inc. financial ratios
See a number that looks wrong?
Close on Nov 18, 2026Market cap $2.09MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross margin | – | 0.26% | 24.4% | 16.3% | -3.0% | – |
| Operating margin | – | -573.8% | -701.1% | -548.8% | -448.1% | – |
| EBITDA margin | – | -573.5% | -700.4% | -548.3% | – | – |
| Pre-tax margin | – | – | -701.0% | -548.7% | – | – |
| Net profit margin | – | -725.0% | -701.0% | -548.7% | -675.7% | – |
| Free cash flow margin | – | -734.0% | -733.8% | -485.3% | – | – |
| Returns on capital | ||||||
| Return on equity | -91.8% | -185.0% | -228.7% | -119.5% | -140.5% | – |
| Return on assets | -51.6% | -142.0% | -149.5% | -96.6% | -56.5% | – |
| Return on tangible assets | -77.2% | -142.0% | -149.5% | -96.6% | -56.5% | – |
| Return on capital employed | -47.2% | -142.3% | -212.7% | -113.4% | -40.8% | – |
| NOPAT | -$6.24M | -$3.54M | -$6.51M | -$7.98M | -$4.45M | – |
| Cash flow quality | ||||||
| OCF / Sales | – | -734.0% | -723.7% | -484.7% | -446.5% | – |
| OCF / Net income | 0.79 | 1.01 | 1.03 | 0.88 | 0.66 | – |
| FCF / OCF | 100.5% | 100.0% | 101.4% | 100.1% | – | – |
| FCF / Net income | 0.79 | 1.01 | 1.05 | 0.88 | – | – |
| FCF / EBITDA | – | 128.0% | 104.8% | 88.5% | – | – |
| Unlevered free cash flow | -$6.92M | -$5.73M | -$8.63M | -$8.93M | – | – |
| Levered free cash flow | -$7.04M | -$5.73M | -$8.63M | -$8.93M | – | – |
| Efficiency | ||||||
| Asset turnover | – | 0.20 | 0.21 | 0.18 | 0.08 | – |
| Fixed asset turnover | – | 12.58 | 17.55 | 160.00 | 114.27 | – |
| Receivables turnover | – | 6.42 | 8.37 | 18.49 | 13.66 | – |
| Days sales outstanding | – | 56.9 | 43.6 | 19.7 | 26.7 | – |
| Payables turnover | – | 1.86 | 0.87 | 1.46 | 1.64 | – |
| Days payables outstanding | – | 196.6 | 418.0 | 250.1 | 222.4 | – |
| Inventory turnover | – | 1.45 | 1.10 | 2.39 | 3.02 | – |
| Days inventory outstanding | – | 252.2 | 332.4 | 153.0 | 120.9 | – |
| Operating cycle | – | 309.0 | 376.0 | 172.7 | 147.6 | – |
| Cash conversion cycle | – | 112.5 | -42.0 | -77.4 | -74.8 | – |
| CapEx to revenue | – | 0.00% | 10.0% | 0.60% | – | – |
| CapEx to OCF | -0.54% | -0.00% | -1.4% | -0.12% | – | – |
| CapEx to depreciation | – | 0.00 | 14.75 | 1.10 | – | – |
| Liquidity | ||||||
| Current ratio | 20.13 | 9.70 | 3.32 | 2.83 | 11.72 | – |
| Quick ratio | 20.13 | 8.53 | 2.78 | 2.37 | 11.37 | – |
| Cash ratio | 19.57 | 7.36 | 2.42 | 1.87 | 10.64 | – |
| Working capital | $12.36M | $2.37M | $3.25M | $3.43M | $13.07M | – |
| Net current asset value | $5.57M | $2.37M | $3.08M | $3.06M | $12.53M | – |
| Leverage | ||||||
| Assets to equity | 1.88 | 1.11 | 1.44 | 1.62 | 1.13 | – |
| Goodwill / Assets | 10.9% | 0.00% | – | – | – | – |
| Intangibles to total assets | 18.0% | 0.00% | – | – | – | – |
| Interest coverage | ||||||
| EBIT / Interest expense | -54.10 | – | – | – | – | – |
| Per share | ||||||
| Revenue per share | – | 1.40 | 13.64 | 323.20 | 219.95 | – |
| EPS (basic) | -7.84 | -19.68 | -176.80 | -1,773.44 | -4,131.00 | – |
| EPS (diluted) | – | -19.68 | -176.80 | -1,773.44 | -4,131.00 | – |
| Book value per share | 6.65 | 4.55 | 41.51 | 637.63 | 2,322.31 | – |
| Tangible book value per share | 4.39 | 4.55 | 41.51 | 637.63 | 2,322.31 | – |
| Cash per share | 5.01 | 3.59 | 39.37 | 617.78 | 2,270.34 | – |
| Operating cash flow per share | -2.77 | -10.28 | -98.69 | -1,566.66 | -981.98 | – |
| Free cash flow per share | -2.79 | -10.28 | -100.06 | -1,568.59 | – | – |
| CapEx per share | 0.02 | 0.00 | 1.37 | 1.93 | – | – |
| Valuation at period end | ||||||
| Market cap | $60.28M | $54.04M | $65.98M | $154.83M | – | – |
| Enterprise value | $56.83M | $51.85M | $60.81M | $148.51M | – | – |
| P/S | – | 69.3x | 56.1x | 84.1x | – | – |
| P/B | 3.6x | 21.3x | 18.4x | 42.7x | – | – |
| P/TBV | 5.4x | 21.3x | 18.4x | 42.7x | – | – |
| P/Gross profit | – | 27,020x | 230x | 518x | – | – |
| P/OCF | -8.6x | -9.4x | -7.8x | -17.4x | – | – |
| EV/Sales | – | 66.5x | 51.7x | 80.7x | – | – |
| EV/Gross profit | – | 25,925x | 212x | 497x | – | – |
| EV/OCF | -8.1x | -9.1x | -7.1x | -16.7x | – | – |
| Earnings yield | -14.7% | -10.5% | -12.5% | -6.5% | – | – |
| FCF yield | -11.7% | -10.6% | -13.1% | -5.8% | – | – |
| Cost structure | ||||||
| R&D to revenue | – | 168.3% | 140.7% | 94.0% | 69.8% | – |
| SG&A to revenue | – | 405.5% | 584.8% | 471.0% | 375.3% | – |
| Stock-based comp to revenue | – | 29.4% | 23.0% | 21.6% | 4.5% | – |
| Per employee | ||||||
| Total employees | 52 | 7 | 9 | 16 | 7 | 7 |
| Revenue per employee | – | $111.43K | $130.67K | $115.00K | $179.57K | – |
| Gross profit per employee | – | $286 | $31.89K | $18.69K | -$5.43K | – |
| Operating profit per employee | -$151.88K | -$639.43K | -$916.11K | -$631.13K | -$804.71K | – |
| Net income per employee | -$170.73K | -$807.86K | -$916.00K | -$631.00K | -$1.21M | – |
| Free cash flow per employee | -$135.33K | -$817.86K | -$958.78K | -$558.13K | – | – |
| Growth | ||||||
| Revenue 1Y growth | – | -33.7% | -36.1% | 46.4% | – | – |
| Revenue 3Y CAGR | – | -14.7% | – | – | – | – |
| Gross profit 1Y growth | – | -99.3% | -4.0% | 886.8% | – | – |
| EBIT 1Y growth | -76.5% | 45.7% | 18.4% | -79.3% | – | – |
| EBITDA 1Y growth | – | 45.7% | 18.3% | – | – | – |
| Net income 1Y growth | -57.0% | 31.4% | 18.3% | -18.9% | – | – |
| Diluted EPS 1Y growth | – | 88.9% | 90.0% | 57.1% | – | – |
| Operating cash flow 1Y growth | -22.3% | 32.7% | 4.6% | -58.9% | – | – |
| Free cash flow 1Y growth | -22.9% | 33.7% | 3.4% | – | – | – |
| CapEx 1Y growth | – | -100.0% | 972.7% | – | – | – |
| CapEx 3Y CAGR | 51.2% | – | – | – | – | – |
| Total assets 1Y growth | 1,026.0% | -45.6% | -12.2% | -60.9% | – | – |
| Total assets 3Y CAGR | 75.2% | -42.8% | – | – | – | – |
| Total equity 1Y growth | 562.6% | -29.2% | -1.4% | -72.6% | 1,227.6% | – |
| Total equity 3Y CAGR | 66.6% | -42.4% | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.